Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Imiquimod

TLR7 ligand
 
ALX-420-039-M100 100 mg 66.00 USD
 
ALX-420-039-M250 250 mg 145.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: BML-CT106

Topical immune response modifier that inhibits angiogenesis. Up-regulates IL-18 and down-regulates MMP-9 through recognition of Toll-like receptor 7 (TLR7) and subsequent activation of MyD88-dependent pathway.

Product Specification

Alternative Name:1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, R-837
 
Formula:C14H16N4
 
MW:240.3
 
CAS:99011-02-6
 
Purity:≥98% (HPLC)
 
Appearance:White to off-white powder.
 
Solubility:Soluble in DMSO (3mg/ml) or dimethyl formamide; slightly soluble in water (warm to 37°C, vortex); insoluble in 100% ethanol.
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
Use/Stability:Stable for up to 1 year after receipt when stored at -20°C. Stock solutions are stable for up to 3 months when stored at -20°C.
 
Handling:After reconstitution, prepare aliquots and store at -20°C.
 
Technical Info/Product Notes:Stimulation of TLR7 can be achieved with 1-10µg/ml of the compound for 6 to 24 hours.
 
420-039
Please mouse over
420-039

Product Literature References

Tamoxifen downregulates MxA expression by suppressing TLR7 expression in PBMCs of males infected with HCV: I.O. Fawzy, et al.; J. Med. Virol. 86, 1113 (2014), Abstract;
Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation: T. Hirai, et al.; J. Immunol. 190, 4805 (2013), Abstract;
Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus: S.S. Tayel, et al.; Arch. Virol. 158, 1755 (2013), Abstract;
Differential regulation of splenic CD8- dendritic cells and marginal zone B cells by Notch ligands: C. Sekine, et al.; Int. Immunol. 21, 295 (2009), Abstract;
Imiquimod as an antiangiogenic agent: V.W. Li, et al.; J. Drugs Dermatol. 4, 708 (2005), Abstract;
Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis: S. Majewski, et al.; Int. J. Dermatol. 44, 14 (2005), Abstract;
In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases: C. Hesling, et al.; Br. J. Dermatol. 150, 761 (2004), Abstract;
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002), Abstract;
Imiquimod applied topically: a novel immune response modifier and new class of drug: R.L. Miller, et al.; Int. J. Immunopharmacol. 21, 1 (1999), Abstract;

General Literature References

Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis: S. Majewski, et al.; Int. J. Dermatol. 44, 14 (2005), Abstract;

Related Products

PBS (endotoxin-free) 

Print as PDF
 
ALX-505-007-LD15 1.5 ml 54.00 USD
 
ALX-505-007-L010 10 ml 102.00 USD
Do you need bulk/larger quantities?
 

ddWater (endotoxin-free) 

7732-18-5 | Print as PDF
 
ALX-505-008-LD15 1.5 ml 38.00 USD
Do you need bulk/larger quantities?
 

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

Product Flyers
Antiviral Signaling
Antiviral Signaling
Download as PDF

Product Flyers
Key TLR Ligands and their Receptors
Key TLR Ligands and their Receptors
Download as PDF

Technical Posters
Disease-Associated Stress Signaling
Disease-Associated Stress Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,